{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:02:48Z","timestamp":1794535368035,"version":"4.9.1"},"reference-count":188,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41571-026-01145-y","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:35:34Z","timestamp":1777365334000},"page":"501-519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The clinical landscape of HIF2\u03b1 inhibitors in oncology"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8700-9312","authenticated-orcid":false,"given":"Eddy","family":"Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-9922","authenticated-orcid":false,"given":"Marc","family":"Machaalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2675-5095","authenticated-orcid":false,"given":"David F.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"1145_CR1","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.hoc.2023.04.011","volume":"37","author":"NH Shirole","year":"2023","unstructured":"Shirole, N. H. & Kaelin, W. G. von-Hippel Lindau and hypoxia-inducible factor at the center of renal cell carcinoma biology. Hematol. Oncol. Clin. North Am. 37, 809\u2013825 (2023).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"1145_CR2","unstructured":"US Food and Drug Administration. FDA approves belzutifan for cancers associated with von Hippel-Lindau disease. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belzutifan-cancers-associated-von-hippel-lindau-disease (2021)."},{"key":"1145_CR3","unstructured":"US Food and Drug Administration. FDA approves belzutifan for advanced renal cell carcinoma. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belzutifan-advanced-renal-cell-carcinoma (2023)."},{"key":"1145_CR4","unstructured":"US Food and Drug Administration. FDA approves belzutifan for pheochromocytoma or paraganglioma. FDA https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma (2025)."},{"key":"1145_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41419-021-03505-1","volume":"12","author":"X Bao","year":"2021","unstructured":"Bao, X. et al. The crosstalk between HIFs and mitochondrial dysfunctions in cancer development. Cell Death Dis. 12,\u00a0215 (2021).","journal-title":"Cell Death Dis."},{"key":"1145_CR6","first-page":"298","volume":"128","author":"WG Kaelin","year":"2017","unstructured":"Kaelin, W. G. The VHL tumor suppressor gene: insights into oxygen sensing and cancer. Trans. Am. Clin. Climatol. Assoc. 128, 298\u2013307 (2017).","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"1145_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1101\/gad.11.1.72","volume":"11","author":"H Tian","year":"1997","unstructured":"Tian, H., McKnight, S. L. & Russell, D. W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11, 72\u201382 (1997).","journal-title":"Genes Dev."},{"key":"1145_CR8","doi-asserted-by":"publisher","first-page":"15504","DOI":"10.1073\/pnas.2533374100","volume":"100","author":"PJA Erbel","year":"2003","unstructured":"Erbel, P. J. A., Card, P. B., Karakuzu, O., Bruick, R. K. & Gardner, K. H. Structural basis for PAS domain heterodimerization in the basic helix\u2013loop\u2013helix-PAS transcription factor hypoxia-inducible factor. Proc. Natl Acad. Sci. USA 100, 15504\u201315509 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1145_CR9","doi-asserted-by":"publisher","first-page":"38102","DOI":"10.1074\/jbc.M504342200","volume":"280","author":"KKW To","year":"2005","unstructured":"To, K. K. W. & Huang, L. E. Suppression of hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) transcriptional activity by the HIF prolyl hydroxylase EGLN1. J. Biol. Chem. 280, 38102\u201338107 (2005).","journal-title":"J. Biol. Chem."},{"key":"1145_CR10","first-page":"8777","volume":"63","author":"N Erez","year":"2003","unstructured":"Erez, N. et al. Expression of prolyl-hydroxylase-1 (PHD1\/EGLN2) suppresses hypoxia inducible factor-1\u03b1 activation and inhibits tumor growth. Cancer Res. 63, 8777\u20138783 (2003).","journal-title":"Cancer Res."},{"key":"1145_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1146\/annurev.biochem.74.082803.133142","volume":"74","author":"WG Kaelin","year":"2005","unstructured":"Kaelin, W. G. Proline hydroxylation and gene expression. Annu. Rev. Biochem. 74, 115\u2013128 (2005).","journal-title":"Annu. Rev. Biochem."},{"key":"1145_CR12","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nature00767","volume":"417","author":"W-C Hon","year":"2002","unstructured":"Hon, W.-C. et al. Structural basis for the recognition of hydroxyproline in HIF-1\u03b1 by pVHL. Nature 417, 975\u2013978 (2002).","journal-title":"Nature"},{"key":"1145_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cca.2008.05.002","volume":"395","author":"S Kaluz","year":"2008","unstructured":"Kaluz, S., Kaluzov\u00e1, M. & Stanbridge, E. J. Regulation of gene expression by hypoxia: integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element. Clinica Chim. Acta 395, 6\u201313 (2008).","journal-title":"Clinica Chim. Acta"},{"key":"1145_CR14","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1128\/MCB.16.9.4604","volume":"16","author":"JA Forsythe","year":"1996","unstructured":"Forsythe, J. A. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 16, 4604\u20134613 (1996).","journal-title":"Mol. Cell Biol."},{"key":"1145_CR15","doi-asserted-by":"publisher","first-page":"21513","DOI":"10.1016\/S0021-9258(20)80571-7","volume":"268","author":"GL Wang","year":"1993","unstructured":"Wang, G. L. & Semenza, G. L. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J. Biol. Chem. 268, 21513\u201321518 (1993).","journal-title":"J. Biol. Chem."},{"key":"1145_CR16","doi-asserted-by":"publisher","first-page":"29083","DOI":"10.1074\/jbc.270.49.29083","volume":"270","author":"BL Ebert","year":"1995","unstructured":"Ebert, B. L., Firth, J. D. & Ratcliffe, P. J. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J. Biol. Chem. 270, 29083\u201329089 (1995).","journal-title":"J. Biol. Chem."},{"key":"1145_CR17","doi-asserted-by":"publisher","first-page":"23757","DOI":"10.1016\/S0021-9258(17)31580-6","volume":"269","author":"GL Semenza","year":"1994","unstructured":"Semenza, G. L., Roth, P. H., Fang, H. M. & Wang, G. L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 269, 23757\u201323763 (1994).","journal-title":"J. Biol. Chem."},{"key":"1145_CR18","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1158\/0008-5472.CAN-05-2519","volume":"66","author":"VA Carroll","year":"2006","unstructured":"Carroll, V. A. & Ashcroft, M. Role of hypoxia-inducible factor (HIF)-1\u03b1 versus HIF-2\u03b1 in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res. 66, 6264\u20136270 (2006).","journal-title":"Cancer Res."},{"key":"1145_CR19","doi-asserted-by":"publisher","first-page":"9336","DOI":"10.1074\/jbc.M411858200","volume":"280","author":"J-P Piret","year":"2005","unstructured":"Piret, J.-P. et al. Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J. Biol. Chem. 280, 9336\u20139344 (2005).","journal-title":"J. Biol. Chem."},{"key":"1145_CR20","first-page":"3014","volume":"62","author":"RS Bindra","year":"2002","unstructured":"Bindra, R. S., Vasselli, J. R., Stearman, R., Linehan, W. M. & Klausner, R. D. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 62, 3014\u20133019 (2002).","journal-title":"Cancer Res."},{"key":"1145_CR21","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1158\/1078-0432.CCR-06-2510","volume":"13","author":"G Bratslavsky","year":"2007","unstructured":"Bratslavsky, G., Sudarshan, S., Neckers, L. & Linehan, W. M. Pseudohypoxic pathways in renal cell carcinoma. Clin. Cancer Res. 13, 4667\u20134671 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1145_CR22","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/(SICI)1097-0142(19991201)86:11+<2478::AID-CNCR4>3.0.CO;2-5","volume":"86","author":"CA Friedrich","year":"1999","unstructured":"Friedrich, C. A. Von Hippel-Lindau syndrome. Cancer 86, 2478\u20132482 (1999).","journal-title":"Cancer"},{"key":"1145_CR23","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-05-3074","volume":"66","author":"RE Banks","year":"2006","unstructured":"Banks, R. E. et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 66, 2000\u20132011 (2006).","journal-title":"Cancer Res."},{"key":"1145_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"CJ Creighton","year":"2013","unstructured":"Creighton, C. J. et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43\u201349 (2013).","journal-title":"Nature"},{"key":"1145_CR25","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1038\/sj.onc.1203938","volume":"19","author":"M Krieg","year":"2000","unstructured":"Krieg, M. et al. Up-regulation of hypoxia-inducible factors HIF-1\u03b1 and HIF-2\u03b1 under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19, 5435\u20135443 (2000).","journal-title":"Oncogene"},{"key":"1145_CR26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc885","volume":"2","author":"WG Kaelin","year":"2002","unstructured":"Kaelin, W. G. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 673\u2013682 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"1145_CR27","doi-asserted-by":"publisher","first-page":"10595","DOI":"10.1073\/pnas.93.20.10595","volume":"93","author":"O Iliopoulos","year":"1996","unstructured":"Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G. & Goldberg, M. A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA 93, 10595\u201310599 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1145_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","volume":"7","author":"MA Selak","year":"2005","unstructured":"Selak, M. A. et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-\u03b1 prolyl hydroxylase. Cancer Cell 7, 77\u201385 (2005).","journal-title":"Cancer Cell"},{"key":"1145_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccr.2007.02.005","volume":"11","author":"PJ Pollard","year":"2007","unstructured":"Pollard, P. J. et al. Targeted inactivation of Fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell 11, 311\u2013319 (2007).","journal-title":"Cancer Cell"},{"key":"1145_CR30","doi-asserted-by":"publisher","first-page":"djv053","DOI":"10.1093\/jnci\/djv053","volume":"107","author":"A Casc\u00f3n","year":"2015","unstructured":"Casc\u00f3n, A. et al. Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene. J. Natl Cancer Inst. 107, djv053 (2015).","journal-title":"J. Natl Cancer Inst."},{"key":"1145_CR31","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bbrc.2005.08.165","volume":"338","author":"WG Kaelin","year":"2005","unstructured":"Kaelin, W. G. The von Hippel\u2013Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem. Biophys. Res. Commun. 338, 627\u2013638 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1145_CR32","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMra1806651","volume":"381","author":"HPH Neumann","year":"2019","unstructured":"Neumann, H. P. H., Young, W. F. & Eng, C. Pheochromocytoma and paraganglioma. N. Engl. J. Med. 381, 552\u2013565 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1145_CR33","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1093\/hmg\/ddi227","volume":"14","author":"PJ Pollard","year":"2005","unstructured":"Pollard, P. J. et al. Accumulation of krebs cycle intermediates and over-expression of HIF1\u03b1 in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14, 2231\u20132239 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"1145_CR34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10689-014-9735-2","volume":"13","author":"FH Menko","year":"2014","unstructured":"Menko, F. H. et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam. Cancer 13, 637\u2013644 (2014).","journal-title":"Fam. Cancer"},{"key":"1145_CR35","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/sj.bjc.6603547","volume":"96","author":"S Sudarshan","year":"2007","unstructured":"Sudarshan, S., Linehan, W. M. & Neckers, L. HIF and fumarate hydratase in renal cancer. Br. J. Cancer 96, 403\u2013407 (2007).","journal-title":"Br. J. Cancer"},{"key":"1145_CR36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ccr.2005.06.017","volume":"8","author":"JS Isaacs","year":"2005","unstructured":"Isaacs, J. S. et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143\u2013153 (2005).","journal-title":"Cancer Cell"},{"key":"1145_CR37","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ccr.2011.09.006","volume":"20","author":"J Adam","year":"2011","unstructured":"Adam, J. et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif\/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20, 524\u2013537 (2011).","journal-title":"Cancer Cell"},{"key":"1145_CR38","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1128\/MCB.01223-06","volume":"27","author":"Y Pan","year":"2007","unstructured":"Pan, Y. et al. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol. Cell Biol. 27, 912\u2013925 (2007).","journal-title":"Mol. Cell Biol."},{"key":"1145_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162568","volume":"11","author":"HS Ban","year":"2016","unstructured":"Ban, H. S. et al. A novel malate dehydrogenase 2 inhibitor suppresses hypoxia-inducible factor-1 by regulating mitochondrial respiration. PLoS ONE\u00a011, e0162568 (2016).","journal-title":"PLoS ONE"},{"key":"1145_CR40","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.3324\/haematol.2023.282913","volume":"108","author":"M Delamare","year":"2023","unstructured":"Delamare, M. et al. Characterization of genetic variants in the EGLN1\/PHD2 gene identified in a European collection of patients with erythrocytosis. Haematologica 108, 3068\u20133085 (2023).","journal-title":"Haematologica"},{"key":"1145_CR41","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1056\/NEJMoa0806277","volume":"359","author":"C Ladroue","year":"2008","unstructured":"Ladroue, C. et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N. Engl. J. Med. 359, 2685\u20132692 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1145_CR42","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1056\/NEJMoa1205119","volume":"367","author":"Z Zhuang","year":"2012","unstructured":"Zhuang, Z. et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N. Engl. J. Med. 367, 922\u2013930 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1145_CR43","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-23-0050","volume":"30","author":"JS Rosenblum","year":"2023","unstructured":"Rosenblum, J. S., Wang, H., Nazari, M. A., Zhuang, Z. & Pacak, K. Pacak-Zhuang syndrome: a model providing new insights into tumor syndromes. Endocr. Relat. Cancer 30, e230050 (2023).","journal-title":"Endocr. Relat. Cancer"},{"key":"1145_CR44","unstructured":"Cole, Y. et al. Expanding the clinical tumor phenotype of the EPAS1-asssociated tumor syndrome. J. Clin. Endocrinol. Metab. (2026)."},{"key":"1145_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100777","volume":"38","author":"JJ Wang","year":"2025","unstructured":"Wang, J. J. et al. ELOC-mutated renal cell carcinoma is a rare indolent tumor with distinctive genomic characteristics. Mod. Pathol. 38, 100777 (2025).","journal-title":"Mod. Pathol."},{"key":"1145_CR46","doi-asserted-by":"publisher","first-page":"120.e21","DOI":"10.1016\/j.urolonc.2025.10.009","volume":"44","author":"CD Vocke","year":"2026","unstructured":"Vocke, C. D. et al. Multigenerational VHL family characterized by pathogenic germline ELOC variant: response to belzutifan. Urol. Oncol. 44, 120.e21\u2013120.e27 (2026).","journal-title":"Urol. Oncol."},{"key":"1145_CR47","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1096\/fj.02-0445fje","volume":"17","author":"MS Wiesener","year":"2003","unstructured":"Wiesener, M. S. et al. Widespread hypoxia-inducible expression of HIF-2\u03b1 in distinct cell populations of different organs. FASEB J. 17, 271\u2013273 (2003).","journal-title":"FASEB J."},{"key":"1145_CR48","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1097\/01.ASN.0000017223.49823.2A","volume":"13","author":"C Rosenberger","year":"2002","unstructured":"Rosenberger, C. et al. Expression of hypoxia-inducible factor-1\u03b1 and -2\u03b1 in hypoxic and ischemic rat kidneys. J. Am. Soc. Nephrol. 13, 1721 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1145_CR49","doi-asserted-by":"publisher","DOI":"10.1172\/JCI174661","volume":"134","author":"M Prange-Barczynska","year":"2024","unstructured":"Prange-Barczynska, M. et al. Hif-2\u03b1 programs oxygen chemosensitivity in chromaffin cells. J. Clin. Invest. 134, e174661 (2024).","journal-title":"J. Clin. Invest."},{"key":"1145_CR50","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1182\/blood.V92.7.2260","volume":"92","author":"MS Wiesener","year":"1998","unstructured":"Wiesener, M. S. et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1\u03b1. Blood 92, 2260\u20132268 (1998).","journal-title":"Blood"},{"key":"1145_CR51","doi-asserted-by":"publisher","first-page":"9361","DOI":"10.1128\/MCB.23.24.9361-9374.2003","volume":"23","author":"C-J Hu","year":"2003","unstructured":"Hu, C.-J., Wang, L.-Y., Chodosh, L. A., Keith, B. & Simon, M. C. Differential roles of hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) and HIF-2\u03b1 in hypoxic gene regulation. Mol. Cell Biol. 23, 9361\u20139374 (2003).","journal-title":"Mol. Cell Biol."},{"key":"1145_CR52","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ccr.2007.07.006","volume":"12","author":"JD Gordan","year":"2007","unstructured":"Gordan, J. D., Thompson, C. B. & Simon, M. C. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12, 108\u2013113 (2007).","journal-title":"Cancer Cell"},{"key":"1145_CR53","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/sj.emboj.7600196","volume":"23","author":"M Koshiji","year":"2004","unstructured":"Koshiji, M. et al. HIF-1\u03b1 induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23, 1949\u20131956 (2004).","journal-title":"EMBO J."},{"key":"1145_CR54","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1038\/sj.onc.1206373","volume":"22","author":"M Baba","year":"2003","unstructured":"Baba, M. et al. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Oncogene 22, 2728\u20132738 (2003).","journal-title":"Oncogene"},{"key":"1145_CR55","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ccr.2007.02.006","volume":"11","author":"JD Gordan","year":"2007","unstructured":"Gordan, J. D., Bertovrt, J. A., Hu, C.-J., Diehl, J. A. & Simon, M. C. HIF-2\u03b1 promotes hypoxic cell proliferation by enhancing c-Myc transcriptional activity. Cancer Cell 11, 335\u2013347 (2007).","journal-title":"Cancer Cell"},{"key":"1145_CR56","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201846401","volume":"20","author":"JA Smythies","year":"2019","unstructured":"Smythies, J. A. et al. Inherent DNA-binding specificities of the HIF-1\u03b1 and HIF-2\u03b1 transcription factors in chromatin. EMBO Rep. 20, e46401 (2019).","journal-title":"EMBO Rep."},{"key":"1145_CR57","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1091\/mbc.e06-05-0419","volume":"18","author":"C-J Hu","year":"2007","unstructured":"Hu, C.-J., Sataur, A., Wang, L., Chen, H. & Simon, M. C. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1\u03b1 and HIF-2\u03b1. Mol. Biol. Cell 18, 4528\u20134542 (2007).","journal-title":"Mol. Biol. Cell"},{"key":"1145_CR58","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.tibs.2012.06.004","volume":"37","author":"MY Koh","year":"2012","unstructured":"Koh, M. Y. & Powis, G. Passing the baton: the HIF switch. Trends Biochem. Sci. 37, 364\u2013372 (2012).","journal-title":"Trends Biochem. Sci."},{"key":"1145_CR59","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/febs.13572","volume":"283","author":"L Ravenna","year":"2016","unstructured":"Ravenna, L., Salvatori, L. & Russo, M. A. HIF3\u03b1: the little we know. FEBS J. 283, 993\u20131003 (2016).","journal-title":"FEBS J."},{"key":"1145_CR60","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3390\/cancers14051259","volume":"14","author":"L Davis","year":"2022","unstructured":"Davis, L. et al. Targeting HIF-2\u03b1 in the tumor microenvironment: redefining the role of HIF-2\u03b1 for solid cancer therapy. Cancers 14, 1259 (2022).","journal-title":"Cancers"},{"key":"1145_CR61","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","volume":"26","author":"P Vaupel","year":"2007","unstructured":"Vaupel, P. & Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26, 225\u2013239 (2007).","journal-title":"Cancer Metastasis Rev."},{"key":"1145_CR62","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3389\/fonc.2018.00224","volume":"8","author":"E Moreno Roig","year":"2018","unstructured":"Moreno Roig, E. et al. Prognostic role of hypoxia-inducible factor-2\u03b1 tumor cell expression in cancer patients: a meta-analysis. Front. Oncol. 8, 224 (2018).","journal-title":"Front. Oncol."},{"key":"1145_CR63","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.1158\/1078-0432.CCR-10-1360","volume":"16","author":"X Lu","year":"2010","unstructured":"Lu, X. & Kang, Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin. Cancer Res. 16, 5928\u20135935 (2010).","journal-title":"Clin. Cancer Res."},{"key":"1145_CR64","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1172\/JCI66715","volume":"123","author":"SC Hanna","year":"2013","unstructured":"Hanna, S. C. et al. HIF1\u03b1 and HIF2\u03b1 independently activate SRC to promote melanoma metastases. J. Clin. Invest. 123, 2078\u20132093 (2013).","journal-title":"J. Clin. Invest."},{"key":"1145_CR65","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ccr.2011.11.017","volume":"21","author":"C Branco-Price","year":"2012","unstructured":"Branco-Price, C. et al. Endothelial cell HIF-1\u03b1 and HIF-2\u03b1 differentially regulate metastatic success. Cancer Cell 21, 52\u201365 (2012).","journal-title":"Cancer Cell"},{"key":"1145_CR66","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1172\/JCI38443C1","volume":"119","author":"WY Kim","year":"2009","unstructured":"Kim, W. Y. et al. HIF2\u03b1 cooperates with RAS to promote lung tumorigenesis in mice. J. Clin. Invest. 119, 3182\u20133182 (2009).","journal-title":"J. Clin. Invest."},{"key":"1145_CR67","doi-asserted-by":"publisher","first-page":"21306","DOI":"10.1073\/pnas.0906432106","volume":"106","author":"A Franovic","year":"2009","unstructured":"Franovic, A., Holterman, C. E., Payette, J. & Lee, S. Human cancers converge at the HIF-2\u03b1 oncogenic axis. Proc. Natl Acad. Sci. USA 106, 21306\u201321311 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1145_CR68","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrurol.2010.47","volume":"7","author":"WM Linehan","year":"2010","unstructured":"Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7, 277\u2013285 (2010).","journal-title":"Nat. Rev. Urol."},{"key":"1145_CR69","doi-asserted-by":"publisher","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","volume":"1","author":"K Kondo","year":"2003","unstructured":"Kondo, K., Kim, W. Y., Lechpammer, M. & Kaelin, W. G. Inhibition of HIF2\u03b1 is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, E83 (2003).","journal-title":"PLoS Biol."},{"key":"1145_CR70","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.4161\/cc.6.22.4947","volume":"6","author":"MA Maynard","year":"2007","unstructured":"Maynard, M. A. et al. Dominant-negative HIF-3\u03b14 suppresses VHL-null renal cell carcinoma progression. Cell Cycle 6, 2810\u20132816 (2007).","journal-title":"Cell Cycle"},{"key":"1145_CR71","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.molcel.2008.12.004","volume":"32","author":"M Zimmer","year":"2008","unstructured":"Zimmer, M. et al. Small-molecule inhibitors of HIF-2a translation link its 5\u2019UTR iron-responsive element to oxygen sensing. Mol. Cell 32, 838\u2013848 (2008).","journal-title":"Mol. Cell"},{"key":"1145_CR72","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbcan.2012.11.002","volume":"1835","author":"C Yan","year":"2013","unstructured":"Yan, C. & Higgins, P. J. Drugging the undruggable: transcription therapy for cancer. Biochim. Biophys. Acta Rev. Cancer 1835, 76\u201385 (2013).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"1145_CR73","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm301847z","volume":"56","author":"JL Rogers","year":"2013","unstructured":"Rogers, J. L. et al. Development of inhibitors of the PAS-B domain of the HIF-2\u03b1 transcription factor. J. Med. Chem. 56, 1739\u20131747 (2013).","journal-title":"J. Med. Chem."},{"key":"1145_CR74","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1073\/pnas.0808092106","volume":"106","author":"TH Scheuermann","year":"2009","unstructured":"Scheuermann, T. H. et al. Artificial ligand binding within the HIF2\u03b1 PAS-B domain of the HIF2 transcription factor. Proc. Natl Acad. Sci. USA 106, 450\u2013455 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1145_CR75","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nchembio.1185","volume":"9","author":"TH Scheuermann","year":"2013","unstructured":"Scheuermann, T. H. et al. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat. Chem. Biol. 9, 271\u2013276 (2013).","journal-title":"Nat. Chem. Biol."},{"key":"1145_CR76","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-16-0473","volume":"76","author":"EM Wallace","year":"2016","unstructured":"Wallace, E. M. et al. A small-molecule antagonist of HIF2\u03b1 is efficacious in preclinical models of renal cell carcinoma. Cancer Res. 76, 5491\u20135500 (2016).","journal-title":"Cancer Res."},{"key":"1145_CR77","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","volume":"36","author":"KD Courtney","year":"2018","unstructured":"Courtney, K. D. et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2\u03b1 antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J. Clin. Oncol. 36, 867\u2013874 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR78","doi-asserted-by":"publisher","first-page":"6876","DOI":"10.1021\/acs.jmedchem.9b00719","volume":"62","author":"R Xu","year":"2019","unstructured":"Xu, R. et al. 3-[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) inhibitor for the treatment of clear cell renal cell carcinoma. J. Med. Chem. 62, 6876\u20136893 (2019).","journal-title":"J. Med. Chem."},{"key":"1145_CR79","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature19796","volume":"539","author":"W Chen","year":"2016","unstructured":"Chen, W. et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539, 112\u2013117 (2016).","journal-title":"Nature"},{"key":"1145_CR80","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature19795","volume":"539","author":"H Cho","year":"2016","unstructured":"Cho, H. et al. On-target efficacy of a HIF-2\u03b1 antagonist in preclinical kidney cancer models. Nature 539, 107\u2013111 (2016).","journal-title":"Nature"},{"key":"1145_CR81","doi-asserted-by":"crossref","unstructured":"Merck buys maker of HIF2\u03b1 inhibitor. Cancer Discov. 9, OF4 (2019).","DOI":"10.1158\/2159-8290.CD-NB2019-070"},{"key":"1145_CR82","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1200\/JCO.2018.36.15_suppl.2508","volume":"36","author":"KP Papadopoulos","year":"2018","unstructured":"Papadopoulos, K. P., Jonasch, E., Zojwalla, N. J., Wang, K. & Bauer, T. M. A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors. J. Clin. Oncol. 36, 2508 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR83","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","volume":"27","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat. Med. 27, 802\u2013805 (2021).","journal-title":"Nat. Med."},{"key":"1145_CR84","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.2020.38.6_suppl.611","volume":"38","author":"TK Choueiri","year":"2020","unstructured":"Choueiri, T. K. et al. Phase I\/II study of the oral HIF-2 \u03b1 inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC). J. Clin. Oncol. 38, 611 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR85","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch, E. et al. Belzutifan for renal cell carcinoma in von Hippel\u2013Lindau disease. N. Engl. J. Med. 385, 2036\u20132046 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1145_CR86","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1200\/JCO.2025.43.16_suppl.4507","volume":"43","author":"V Narayan","year":"2025","unstructured":"Narayan, V. et al. Hypoxia-inducible factor-2\u03b1 (HIF-2\u03b1) inhibitor belzutifan in von Hippel-Lindau (VHL) disease\u2013associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study. J. Clin. Oncol. 43, 4507 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR87","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S1470-2045(24)00389-9","volume":"25","author":"O Iliopoulos","year":"2024","unstructured":"Iliopoulos, O. et al. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol. 25, 1325\u20131336 (2024).","journal-title":"Lancet Oncol."},{"key":"1145_CR88","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1158\/1078-0432.CCR-23-2592","volume":"30","author":"T Else","year":"2024","unstructured":"Else, T. et al. Belzutifan for von Hippel\u2013Lindau disease: pancreatic lesion population of the phase 2 LITESPARK-004 study. Clin. Cancer Res. 30, 1750\u20131757 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1145_CR89","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1200\/JCO.2026.44.7_suppl.494","volume":"44","author":"K Gong","year":"2026","unstructured":"Gong, K. et al. Phase 2 trial of belzutifan in participants from China and Japan with von hippel-lindau disease-associated tumors: results from LITESPARK-015 cohort B1. J. Clin. Oncol. 44, 494 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR90","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri, T. K. et al. Belzutifan versus everolimus for advanced renal-cell carcinoma. N. Engl. J. Med. 391, 710\u2013721 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1145_CR91","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2024.08.2338","volume":"35","author":"N Agarwal","year":"2024","unstructured":"Agarwal, N. et al. Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. Ann. Oncol. 35, 1148\u20131156 (2024).","journal-title":"Ann. Oncol."},{"key":"1145_CR92","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1021\/acs.orglett.4c04501","volume":"27","author":"G Mata","year":"2025","unstructured":"Mata, G. et al. Stereodivergent synthesis of the vicinal difluorinated tetralin of casdatifan enabled by Ru-catalyzed transfer hydrogenation. Org. Lett. 27, 833\u2013839 (2025).","journal-title":"Org. Lett."},{"key":"1145_CR93","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1002\/bcp.70169","volume":"91","author":"M Ghasemi","year":"2025","unstructured":"Ghasemi, M. et al. Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia-inducible factor-2\u03b1 inhibitor, in healthy participants. Br. J. Clin. Pharmacol. 91, 3366\u20133377 (2025).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1145_CR94","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1200\/JCO.2026.44.7_suppl.493","volume":"44","author":"TK Choueiri","year":"2026","unstructured":"Choueiri, T. K. et al. Activity and biomarker analyses with casdatifan (cas), a next-generation HIF-2\u03b1 inhibitor, in refractory clear cell renal cell carcinoma (ccRCC): results from ARC-20. J. Clin. Oncol. 44, 493 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR95","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1158\/1078-0432.CCR-24-2618","volume":"31","author":"SK Pal","year":"2025","unstructured":"Pal, S. K. et al. A phase I dose-escalation study of the HIF-2 alpha inhibitor DFF332 in patients with advanced clear-cell renal cell carcinoma. Clin. Cancer Res.\u00a031, 1847\u20131855 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1145_CR96","unstructured":"Seymour, C. NKT2152 data reinforce the importance of HIF2\u03b1 inhibition in advanced clear cell RCC. OncLive https:\/\/www.onclive.com\/view\/nkt2152-data-reinforce-the-importance-of-hif2-inhibition-in-advanced-clear-cell-rcc (2026)."},{"key":"1145_CR97","doi-asserted-by":"publisher","first-page":"S1011","DOI":"10.1016\/j.annonc.2024.08.1783","volume":"35","author":"E Jonasch","year":"2024","unstructured":"Jonasch, E. et al. 1690O NKT2152, a novel oral HIF-2\u03b1 inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): preliminary results of a phase I\/II study. Ann. Oncol. 35, S1011\u2013S1012 (2024).","journal-title":"Ann. Oncol."},{"key":"1145_CR98","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1158\/1538-7445.AM2023-494","volume":"83","author":"P Wang","year":"2023","unstructured":"Wang, P. et al. Abstract 494: BPI-452080: a potent and selective HIF-2\u03b1 inhibitor for the treatment of clear cell renal cell carcinoma, von Hippel-Lindau disease, and other solid tumors. Cancer Res. 83, 494 (2023).","journal-title":"Cancer Res."},{"key":"1145_CR99","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1538-7445.AM2024-2096","volume":"84","author":"YS Green","year":"2024","unstructured":"Green, Y. S., dos Santos, M. F., Ciofi-Baffoni, S., Liu, X. & Koh, M. Y. Abstract 2096: a novel, orally available ferroptosis inducer targeting Fe-S assembly with significant in vivo anti-tumor efficacy. Cancer Res. 84, 2096 (2024).","journal-title":"Cancer Res."},{"key":"1145_CR100","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00109-025-02635-9","volume":"104","author":"Z Wang","year":"2026","unstructured":"Wang, Z., Kong, D. & Wei, W. The role of ferroptosis in renal cell carcinoma: molecular mechanisms and therapeutic implications. J. Mol. Med. 104, 22 (2026).","journal-title":"J. Mol. Med."},{"key":"1145_CR101","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1158\/1535-7163.MCT-17-0471","volume":"17","author":"SC Wong","year":"2018","unstructured":"Wong, S. C. et al. HIF2\u03b1-targeted RNAi therapeutic inhibits clear cell renal cell carcinoma. Mol. Cancer Therapeut. 17, 140\u2013149 (2018).","journal-title":"Mol. Cancer Therapeut."},{"key":"1145_CR102","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.1158\/1538-7445.AM2019-4775","volume":"79","author":"SC Wong","year":"2019","unstructured":"Wong, S. C. et al. Abstract 4775: Optimizing the potency and dosing design for ARO-HIF2: an RNAi therapeutic for clear cell renal cell carcinoma. Cancer Res. 79, 4775 (2019).","journal-title":"Cancer Res."},{"key":"1145_CR103","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.1158\/1078-0432.CCR-22-0963","volume":"28","author":"Y Ma","year":"2022","unstructured":"Ma, Y. et al. HIF2 inactivation and tumor suppression with a tumor-directed RNA-silencing drug in mice and humans. Clin. Cancer Res. 28, 5405\u20135418 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1145_CR104","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1158\/1078-0432.CCR-23-3029","volume":"30","author":"J Brugarolas","year":"2024","unstructured":"Brugarolas, J. et al. A first-in-human phase 1 study of a tumor-directed RNA-interference drug against HIF2\u03b1 in patients with advanced clear cell renal cell carcinoma. Clin. Cancer Res. 30, 2402\u20132411 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1145_CR105","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1200\/JCO.2025.43.5_suppl.549","volume":"43","author":"TK Choueiri","year":"2025","unstructured":"Choueiri, T. K. et al. Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). J. Clin. Oncol. 43, 549 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR106","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1200\/JCO.2026.44.7_suppl.505","volume":"44","author":"L Albiges","year":"2026","unstructured":"Albiges, L. et al. KEYMAKER-U03 substudy 03B: novel investigative regimens for previously treated advanced clear cell renal cell carcinoma (ccRCC). J. Clin. Oncol. 44, 505 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR107","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2217\/fon-2022-0802","volume":"19","author":"RJ Motzer","year":"2023","unstructured":"Motzer, R. J. et al. LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1\/PD-L1 therapy. Future Oncol. 19, 113\u2013121 (2023).","journal-title":"Future Oncol."},{"key":"1145_CR108","doi-asserted-by":"publisher","first-page":"LBA417","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA417","volume":"44","author":"RJ Motzer","year":"2026","unstructured":"Motzer, R. J. et al. Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti\u2013PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study. J. Clin. Oncol. 44, LBA417 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR109","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1200\/JCO.2024.42.16_suppl.4537","volume":"42","author":"X Sheng","year":"2024","unstructured":"Sheng, X. et al. Belzutifan plus lenvatinib (len) for Chinese patients (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): preliminary results of cohort 1 of the phase 1 LITESPARK-010 study. J. Clin. Oncol.\u00a042, 4537\u00a0(2024).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR110","doi-asserted-by":"publisher","first-page":"S1313","DOI":"10.1016\/j.annonc.2025.08.3230","volume":"36","author":"X Sheng","year":"2025","unstructured":"Sheng, X. et al. 2615P Belzutifan plus lenvatinib for Chinese participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): updated results of cohort 1 of the LITESPARK-010 study. Ann. Oncol. 36, S1313 (2025).","journal-title":"Ann. Oncol."},{"key":"1145_CR111","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2025.10.010","volume":"37","author":"C Suarez","year":"2025","unstructured":"Suarez, C. et al. Novel pembrolizumab-based treatments as first-line therapy in advanced clear cell renal cell carcinoma: Substudy 03A of the open-label, umbrella platform, phase I\/II KEYMAKER-U03 trial. Ann. Oncol. 37, 229\u2013240 (2025).","journal-title":"Ann. Oncol."},{"key":"1145_CR112","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.23.01569","volume":"42","author":"RJ Motzer","year":"2024","unstructured":"Motzer, R. J. et al. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of clear, a phase III study. J. Clin. Oncol. 42, 1222\u20131228 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR113","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2025.09.006","volume":"37","author":"RJ Motzer","year":"2026","unstructured":"Motzer, R. J. et al. Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial. Ann. Oncol. 37, 33\u201343 (2026).","journal-title":"Ann. Oncol."},{"key":"1145_CR114","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","volume":"31","author":"BI Rini","year":"2025","unstructured":"Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial. Nat. Med. 31, 3475\u20133484 (2025).","journal-title":"Nat. Med."},{"key":"1145_CR115","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.2217\/fon-2023-0283","volume":"19","author":"TK Choueiri","year":"2023","unstructured":"Choueiri, T. K. et al. LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma. Future Oncol. 19, 2631\u20132640 (2023).","journal-title":"Future Oncol."},{"key":"1145_CR116","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1200\/JCO.2025.43.16_suppl.4506","volume":"43","author":"TK Choueiri","year":"2025","unstructured":"Choueiri, T. K. et al. Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma. J. Clin. Oncol. 43, 4506 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR117","unstructured":"ASCO 2025: Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma. UroToday https:\/\/www.urotoday.com\/conference-highlights\/asco-2025\/asco-2025-kidney-cancer\/160907-asco-2025-combination-casdatifan-plus-cabozantinib-expansion-cohort-of-phase-1-arc-20-study-in-previously-treated-patients-with-clear-cell-renal-cell-carcinoma.html (2025)."},{"key":"1145_CR118","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1158\/1538-7445.AM2016-4022","volume":"76","author":"G Han","year":"2016","unstructured":"Han, G. et al. Abstract 4022: PT2385, a novel HIF-2\u03b1 antagonist, combines with checkpoint inhibitor antibodies to inhibit tumor growth in preclinical models by modulating myeloid cells and enhancing T cell infiltration. Cancer Res. 76, 4022 (2016).","journal-title":"Cancer Res."},{"key":"1145_CR119","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1111\/bph.70075","volume":"182","author":"PG Schweickert","year":"2025","unstructured":"Schweickert, P. G. et al. Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF-2\u03b1 dependent transcription. Br. J. Pharmacol. 182, 4147\u20134167 (2025).","journal-title":"Br. J. Pharmacol."},{"key":"1145_CR120","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/JCO.2019.37.7_suppl.558","volume":"37","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Results from a phase I expansion cohort of the first-in-class oral HIF-2\u03b1 inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC. J. Clin. Oncol. 37, 558 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR121","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","volume":"390","author":"TK Choueiri","year":"2024","unstructured":"Choueiri, T. K. et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N. Engl. J. Med. 390, 1359\u20131371 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1145_CR122","doi-asserted-by":"publisher","first-page":"TPS4602","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4602","volume":"40","author":"TK Choueiri","year":"2022","unstructured":"Choueiri, T. K. et al. LITESPARK-022: a phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC). J. Clin. Oncol. 40, TPS4602 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR123","doi-asserted-by":"publisher","first-page":"LBA418","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA418","volume":"44","author":"TK Choueiri","year":"2026","unstructured":"Choueiri, T. K. et al. Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): the randomized phase 3 LITESPARK-022 study. J. Clin. Oncol. 44, LBA418 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR124","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.cell.2025.01.046","volume":"188","author":"Q Jiang","year":"2025","unstructured":"Jiang, Q. et al. HIF regulates multiple translated endogenous retroviruses: implications for cancer immunotherapy. Cell 188, 1807\u20131827.e34 (2025).","journal-title":"Cell"},{"key":"1145_CR125","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.cell.2019.10.007","volume":"179","author":"DJ Clark","year":"2019","unstructured":"Clark, D. J. et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell 179, 964\u2013983.e31 (2019).","journal-title":"Cell"},{"key":"1145_CR126","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/ijc.11665","volume":"109","author":"Y Hedberg","year":"2004","unstructured":"Hedberg, Y., Ljungberg, B., Roos, G. & Landberg, G. Retinoblastoma protein in human renal cell carcinoma in relation to alterations in G1\/S regulatory proteins. Int. J. Cancer 109, 189\u2013193 (2004).","journal-title":"Int. J. Cancer"},{"key":"1145_CR127","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/ng.2204","volume":"44","author":"J Sch\u00f6del","year":"2012","unstructured":"Sch\u00f6del, J. et al. Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. Nat. Genet. 44, 420\u2013425 (2012).","journal-title":"Nat. Genet."},{"key":"1145_CR128","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aay0482","volume":"12","author":"HE Nicholson","year":"2019","unstructured":"Nicholson, H. E. et al. HIF-independent synthetic lethality between CDK4\/6 inhibition and VHL loss across species. Sci. Signal. 12, eaay0482 (2019).","journal-title":"Sci. Signal."},{"key":"1145_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102318","volume":"23","author":"BA McGregor","year":"2025","unstructured":"McGregor, B. A. et al. CDK4\/6 inhibition with abemaciclib in patients with previously treated advanced renal cell carcinoma. Clin. Genitourin. Cancer 23, 102318 (2025).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1145_CR130","doi-asserted-by":"publisher","first-page":"TPS747","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS747","volume":"41","author":"DF McDermott","year":"2023","unstructured":"McDermott, D. F. et al. LITESPARK-024: a randomized phase 1\/2 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma. J. Clin. Oncol. 41, TPS747 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR131","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.2026.44.7_suppl.423","volume":"44","author":"DF McDermott","year":"2026","unstructured":"McDermott, D. F. et al. Ascending dose escalation of belzutifan plus palbociclib for previously treated advanced clear cell renal cell carcinoma (ccRCC): phase 1\/2 LITESPARK-024 study part 1. J. Clin. Oncol. 44, 423 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR132","doi-asserted-by":"publisher","first-page":"8977","DOI":"10.1093\/nar\/gkaa608","volume":"48","author":"Y Chikashige","year":"2020","unstructured":"Chikashige, Y. et al. Gcn2 eIF2\u03b1 kinase mediates combinatorial translational regulation through nucleotide motifs and uORFs in target mRNAs. Nucleic Acids Res. 48, 8977\u20138992 (2020).","journal-title":"Nucleic Acids Res."},{"key":"1145_CR133","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1158\/1538-7445.AM2024-4615","volume":"84","author":"ME Stokes","year":"2024","unstructured":"Stokes, M. E. et al. Abstract 4615: HC-7366, a potent GCN2 activator, complements belzutifan, a HIF-2\u03b1 antagonist, by providing combination benefit in belzutifan-sensitive models and monotherapy activity in belzutifan-resistant models. Cancer Res. 84, 4615 (2024).","journal-title":"Cancer Res."},{"key":"1145_CR134","first-page":"TPS609","volume":"43","author":"NJ Shah","year":"2025","unstructured":"Shah, N. J. et al. A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605). J. Clin. Oncol. 43, TPS609 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR135","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1172\/JCI30117","volume":"117","author":"EB Rankin","year":"2007","unstructured":"Rankin, E. B. et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J. Clin. Invest. 117, 1068\u20131077 (2007).","journal-title":"J. Clin. Invest."},{"key":"1145_CR136","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1182\/hematology.2024000655","volume":"2024","author":"VH Haase","year":"2024","unstructured":"Haase, V. H., Tanaka, T. & Koury, M. J. Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease. Hematology 2024, 409\u2013418 (2024).","journal-title":"Hematology"},{"key":"1145_CR137","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1093\/oncolo\/oyae181.004","volume":"29","author":"TK Choueiri","year":"2024","unstructured":"Choueiri, T. K. et al. 39 Safety profile of belzutifan monotherapy in patients with renal cell carcinoma: a pooled analysis of 4 clinical trials. Oncologist 29, S2\u2013S3 (2024).","journal-title":"Oncologist"},{"key":"1145_CR138","unstructured":"US Food and Drug Administration. WELIREG (belzutifan) tablets, for oral use. FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215383s000lbl.pdf (2024)."},{"key":"1145_CR139","doi-asserted-by":"publisher","first-page":"10605","DOI":"10.1200\/JCO.2025.43.16_suppl.10605","volume":"43","author":"P Siqueira Do Amaral","year":"2025","unstructured":"Siqueira Do Amaral, P. et al. Long-term safety of belzutifan in von Hippel-Lindau syndrome: a single-center experience. J. Clin. Oncol. 43, 10605 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR140","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(25)00099-3","volume":"26","author":"R Srinivasan","year":"2025","unstructured":"Srinivasan, R. et al. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol. 26, 571\u2013582 (2025).","journal-title":"Lancet Oncol."},{"key":"1145_CR141","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1113\/JP271050","volume":"594","author":"EJ Hodson","year":"2016","unstructured":"Hodson, E. J. et al. Regulation of ventilatory sensitivity and carotid body proliferation in hypoxia by the PHD2\/HIF-2 pathway. J. Physiol. 594, 1179\u20131195 (2016).","journal-title":"J. Physiol."},{"key":"1145_CR142","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1172\/JCI133194","volume":"130","author":"X Cheng","year":"2020","unstructured":"Cheng, X. et al. Marked and rapid effects of pharmacological HIF-2\u03b1 antagonism on hypoxic ventilatory control. J. Clin. Invest. 130, 2237\u20132251 (2020).","journal-title":"J. Clin. Invest."},{"key":"1145_CR143","first-page":"30","volume":"19","author":"LA Poliakova","year":"1974","unstructured":"Poliakova, L. A. Familial erythrocytosis among the residents of the Chuvash ASSR [Russian]. Probl. Gematol. Pereliv. Krovi 19, 30\u201333 (1974).","journal-title":"Probl. Gematol. Pereliv. Krovi"},{"key":"1145_CR144","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1172\/JCI36362","volume":"120","author":"MM Hickey","year":"2010","unstructured":"Hickey, M. M. et al. The von Hippel\u2013Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J. Clin. Invest. 120, 827\u2013839 (2010).","journal-title":"J. Clin. Invest."},{"key":"1145_CR145","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1182\/blood.2020009138","volume":"137","author":"MC Ghosh","year":"2021","unstructured":"Ghosh, M. C. et al. Therapeutic inhibition of HIF-2\u03b1 reverses polycythemia and pulmonary hypertension in murine models of human diseases. Blood 137, 2509\u20132519 (2021).","journal-title":"Blood"},{"key":"1145_CR146","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1164\/rccm.201710-2079OC","volume":"198","author":"Z Dai","year":"2018","unstructured":"Dai, Z. et al. Therapeutic targeting of vascular remodeling and right heart failure in pulmonary arterial hypertension with a HIF-2\u03b1 inhibitor. Am. J. Respir. Crit. Care Med. 198, 1423\u20131434 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1145_CR147","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1056\/NEJMc2411843","volume":"391","author":"H Alkaissi","year":"2024","unstructured":"Alkaissi, H., Pacak, K. & Rosenblum, J. Belzutifan versus everolimus for advanced renal-cell carcinoma. N. Engl. J. Med. 391, 2061\u20132062 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1145_CR148","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2026.44.7_suppl.488","volume":"44","author":"TR McFarland","year":"2026","unstructured":"McFarland, T. R. et al. Incidence of symptomatic hypoxia in a high-altitude cohort of patients with renal cell carcinoma (RCC) treated with belzutifan. J. Clin. Oncol. 44, 488 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR149","doi-asserted-by":"publisher","first-page":"A003","DOI":"10.1158\/1535-7163.TARG-25-A003","volume":"24","author":"G Roberti de Oliveira","year":"2025","unstructured":"Roberti de Oliveira, G. et al. Abstract A003: baseline levels of HIF2 target proteins and response to the HIF2\u03b1 inhibitor NKT2152 in patients with metastatic clear cell renal cell carcinoma. Mol. Cancer Ther. 24, A003 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"1145_CR150","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1200\/JCO.2026.44.7_suppl.545","volume":"44","author":"N Agarwal","year":"2026","unstructured":"Agarwal, N. et al. Biomarker analysis from the phase 2 LITESPARK-013 study of 2 different belzutifan (bel) doses in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC). J. Clin. Oncol. 44, 545 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR151","doi-asserted-by":"publisher","first-page":"A023","DOI":"10.1158\/1535-7163.TARG-25-A023","volume":"24","author":"Y Guan","year":"2025","unstructured":"Guan, Y. et al. Abstract A023: erythropoietin (EPO) is a pharmacodynamic biomarker for systemic HIF-2\u03b1 inhibition that correlates with the clinical activity of casdatifan. Mol. Cancer Ther. 24, A023 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"1145_CR152","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/JCO.2026.44.7_suppl.528","volume":"44","author":"Y-W Chen","year":"2026","unstructured":"Chen, Y.-W. et al. Genomic and clinical correlates of belzutifan treatment in renal cell carcinoma (RCC): a retrospective analysis of 240 RCC patients. J. Clin. Oncol. 44, 528 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR153","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1200\/JCO.2026.44.7_suppl.475","volume":"44","author":"P Mathews","year":"2026","unstructured":"Mathews, P., Gruber, J., Schoen, M. W., Pachynski, R. K. & Knoche, E. M. Real-world outcomes of clear-cell renal cell carcinoma (ccRCC) patients treated with belzutifan stratified by von Hippel-Lindau (VHL) status. J. Clin. Oncol. 44, 475 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR154","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nature14883","volume":"524","author":"D Wu","year":"2015","unstructured":"Wu, D., Potluri, N., Lu, J., Kim, Y. & Rastinejad, F. Structural integration in hypoxia-inducible factors. Nature 524, 303\u2013308 (2015).","journal-title":"Nature"},{"key":"1145_CR155","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41589-019-0234-5","volume":"15","author":"D Wu","year":"2019","unstructured":"Wu, D. et al. Bidirectional modulation of HIF-2 activity through chemical ligands. Nat. Chem. Biol. 15, 367\u2013376 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"1145_CR156","doi-asserted-by":"publisher","first-page":"37843","DOI":"10.1021\/acsomega.4c03777","volume":"9","author":"V Natarajan","year":"2024","unstructured":"Natarajan, V., Satalkar, V., Gumbart, J. C. & Torres, M. Molecular dynamics reveals altered interactions between belzutifan and HIF-2 with natural variant G323E or proximal phosphorylation at T324. ACS Omega 9, 37843\u201337855 (2024).","journal-title":"ACS Omega"},{"key":"1145_CR157","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-19-1459","volume":"26","author":"KD Courtney","year":"2020","unstructured":"Courtney, K. D. et al. HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma. Clin. Cancer Res. 26, 793\u2013803 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1145_CR158","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2120403119","volume":"119","author":"LA Stransky","year":"2022","unstructured":"Stransky, L. A. et al. Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. Proc. Natl Acad. Sci. USA 119, e2120403119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1145_CR159","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003215.12","volume":"209","author":"M Basin","year":"2023","unstructured":"Basin, M. et al. MP04-12 pharmacological inhibition of the molecular chaperone HSP70 overcomes belzutifan resistance in CCRCC. J. Urol. 209, e37 (2023).","journal-title":"J. Urol."},{"key":"1145_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06450-x","volume":"15","author":"R Liu","year":"2024","unstructured":"Liu, R. et al. FKBP10 promotes clear cell renal cell carcinoma progression and regulates sensitivity to the HIF2\u03b1 blockade by facilitating LDHA phosphorylation. Cell Death Dis. 15, 64 (2024).","journal-title":"Cell Death Dis."},{"key":"1145_CR161","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.565","volume":"6","author":"J Zhao","year":"2015","unstructured":"Zhao, J., Du, F., Shen, G., Zheng, F. & Xu, B. The role of hypoxia-inducible factor-2 in digestive system cancers. Cell Death Dis. 6, e1600 (2015).","journal-title":"Cell Death Dis."},{"key":"1145_CR162","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4252\/wjsc.v12.i1.87","volume":"12","author":"J Bai","year":"2020","unstructured":"Bai, J. et al. HIF-2\u03b1 regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer via PI3K\/AKT\/mTOR signaling. World J. Stem Cell 12, 87\u201399 (2020).","journal-title":"World J. Stem Cell"},{"key":"1145_CR163","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143691","volume":"131","author":"R Singhal","year":"2021","unstructured":"Singhal, R. et al. HIF-2\u03b1 activation potentiates oxidative cell death in colorectal cancers by increasing cellular iron. J. Clin. Invest. 131, e143691 (2021).","journal-title":"J. Clin. Invest."},{"key":"1145_CR164","doi-asserted-by":"publisher","DOI":"10.1177\/1533033821990010","volume":"20","author":"D Pavlakis","year":"2021","unstructured":"Pavlakis, D. et al. Hypoxia-inducible factor 2a expression is positively correlated with Gleason score in prostate cancer. Technol. Cancer Res. Treat. 20, 1533033821990010 (2021).","journal-title":"Technol. Cancer Res. Treat."},{"key":"1145_CR165","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa2110051","volume":"385","author":"J Kamihara","year":"2021","unstructured":"Kamihara, J. et al. Belzutifan, a potent HIF2\u03b1 inhibitor, in the Pacak\u2013Zhuang syndrome. N. Engl. J. Med. 385, 2059\u20132065 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1145_CR166","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMc2409427","volume":"391","author":"H Alkaissi","year":"2024","unstructured":"Alkaissi, H. et al. Rapid cardiovascular response to belzutifan in HIF2A-mediated paraganglioma. N. Engl. J. Med. 391, 1552\u20131555 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1145_CR167","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1056\/NEJMoa2504964","volume":"393","author":"C Jimenez","year":"2025","unstructured":"Jimenez, C. et al. Belzutifan for advanced pheochromocytoma or paraganglioma. N. Engl. J. Med. 393, 2012\u20132022 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1145_CR168","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.eprac.2025.09.204","volume":"32","author":"H Alkaissi","year":"2026","unstructured":"Alkaissi, H. et al. Belzutifan for HIF2A-related pheochromocytoma and paraganglioma: a retrospective study of real-world data. Endocr. Pract. 32, 201\u2013205 (2026).","journal-title":"Endocr. Pract."},{"key":"1145_CR169","doi-asserted-by":"publisher","first-page":"TPS425","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS425","volume":"42","author":"C Rojas","year":"2024","unstructured":"Rojas, C. et al. Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma. J. Clin. Oncol. 42, TPS425 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR170","doi-asserted-by":"publisher","first-page":"11238","DOI":"10.18632\/oncotarget.7167","volume":"7","author":"MW Alam","year":"2016","unstructured":"Alam, M. W. et al. HIF2\u03b1 contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells. Oncotarget 7, 11238\u201311250 (2016).","journal-title":"Oncotarget"},{"key":"1145_CR171","doi-asserted-by":"publisher","first-page":"26823","DOI":"10.1073\/pnas.1911584116","volume":"116","author":"X Fu","year":"2019","unstructured":"Fu, X. et al. FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proc. Natl Acad. Sci. USA 116, 26823\u201326834 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1145_CR172","doi-asserted-by":"publisher","first-page":"TPS1124","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS1124","volume":"43","author":"B Lim","year":"2025","unstructured":"Lim, B., Jia, L., Sudheendra, P. K. & Hirshfield, K. M. LITESPARK-029: a phase 2, randomized, open-label study of belzutifan plus fulvestrant in participants with estrogen receptor\u2013positive, HER2-negative unresectable locally advanced or metastatic breast cancer after progression on previous endocrine therapy. J. Clin. Oncol. 43, TPS1124 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR173","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.4155\/fmc-2018-0163","volume":"10","author":"JJ Renfrow","year":"2018","unstructured":"Renfrow, J. J. et al. Hypoxia-inducible factor 2\u03b1: a novel target in gliomas. Future Med. Chem. 10, 2227\u20132236 (2018).","journal-title":"Future Med. Chem."},{"key":"1145_CR174","doi-asserted-by":"publisher","first-page":"15195","DOI":"10.1038\/s41598-020-72290-2","volume":"10","author":"JJ Renfrow","year":"2020","unstructured":"Renfrow, J. J. et al. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Sci. Rep. 10, 15195 (2020).","journal-title":"Sci. Rep."},{"key":"1145_CR175","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00018-025-05642-8","volume":"82","author":"FI Espinoza","year":"2025","unstructured":"Espinoza, F. I. et al. Targeting HIF-2\u03b1 in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade. Cell Mol. Life Sci. 82, 119 (2025).","journal-title":"Cell Mol. Life Sci."},{"key":"1145_CR176","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11060-023-04456-7","volume":"165","author":"R Strowd","year":"2023","unstructured":"Strowd, R. et al. Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma. J. Neurooncol 165, 101\u2013112 (2023).","journal-title":"J. Neurooncol"},{"key":"1145_CR177","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1200\/JCO.2024.42.16_suppl.2054","volume":"42","author":"RE Strowd","year":"2024","unstructured":"Strowd, R. E. et al. Phase 1 LITESPARK-001 study of belzutifan in advanced solid tumors: results of the glioblastoma cohort. J. Clin. Oncol. 42, 2054 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR178","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41388-023-02680-z","volume":"42","author":"S Cameron","year":"2023","unstructured":"Cameron, S. et al. Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer. Oncogene 42, 1693\u20131703 (2023).","journal-title":"Oncogene"},{"key":"1145_CR179","doi-asserted-by":"publisher","first-page":"TPS250","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS250","volume":"42","author":"EY Yu","year":"2024","unstructured":"Yu, E. Y. et al. Phase 1b\/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J. J. Clin. Oncol. 42, TPS250 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1145_CR180","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1001\/jamaoncol.2019.2311","volume":"5","author":"JS Lee","year":"2019","unstructured":"Lee, J. S. & Ruppin, E. Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1. JAMA Oncol. 5, 1614\u20131618 (2019).","journal-title":"JAMA Oncol."},{"key":"1145_CR181","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/212810","volume":"2011","author":"V Tjomsland","year":"2011","unstructured":"Tjomsland, V. et al. The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Clin. Dev. Immunol. 2011, 212810 (2011).","journal-title":"Clin. Dev. Immunol."},{"key":"1145_CR182","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1053\/j.gastro.2022.02.024","volume":"162","author":"CJ Garcia Garcia","year":"2022","unstructured":"Garcia Garcia, C. J. et al. Stromal HIF2 regulates immune suppression in the pancreatic cancer microenvironment. Gastroenterology 162, 2018\u20132031 (2022).","journal-title":"Gastroenterology"},{"key":"1145_CR183","doi-asserted-by":"publisher","first-page":"S1008","DOI":"10.1016\/j.annonc.2025.08.2338","volume":"36","author":"J Capdevila","year":"2025","unstructured":"Capdevila, J. et al. 1710MO Belzutifan for advanced pancreatic neuroendocrine tumors (panNETs): results from cohort A2 of the phase II LITESPARK-015 study. Ann. Oncol. 36, S1008\u2013S1009 (2025).","journal-title":"Ann. Oncol."},{"key":"1145_CR184","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1097\/01.ju.0000092764.81308.6a","volume":"170","author":"HL Kim","year":"2003","unstructured":"Kim, H. L. et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J. Urol. 170, 1742\u20131746 (2003).","journal-title":"J. Urol."},{"key":"1145_CR185","first-page":"132","volume":"15","author":"R Sun","year":"2021","unstructured":"Sun, R. et al. Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: results from Canadian Kidney Cancer Information System. Can. Urol. Assoc. J. 15, 132\u2013137 (2021).","journal-title":"Can. Urol. Assoc. J."},{"key":"1145_CR186","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.4161\/cc.9.18.12931","volume":"9","author":"M Manisterski","year":"2010","unstructured":"Manisterski, M., Golan, M., Amir, S., Weisman, Y. & Mabjeesh, N. Hypoxia induces PTHrP gene transcription in human cancer cells through the HIF-2\u03b1. Cell Cycle 9, 3747\u20133753 (2010).","journal-title":"Cell Cycle"},{"key":"1145_CR187","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1158\/2159-8290.CD-25-0638","volume":"15","author":"A Mal","year":"2025","unstructured":"Mal, A. et al. HIF-2-dependent regulation of PTHrP and paraneoplastic hypercalcemia in aggressive clear-cell renal cell carcinoma. Cancer Discov. 15, 2485\u20132504 (2025).","journal-title":"Cancer Discov."},{"key":"1145_CR188","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41591-025-04054-2","volume":"32","author":"M Abu-Remaileh","year":"2026","unstructured":"Abu-Remaileh, M. et al. Targeting of HIF2-driven cachexia in kidney cancer. Nat. Med. 32, 245\u2013257 (2026).","journal-title":"Nat. Med."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01145-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01145-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01145-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:02:31Z","timestamp":1782302551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01145-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":188,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01145-y","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"23 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.S. reports institutional research funding from EMD Serono, Genentech\/Roche and OncoHost. D.F.McD. has served as consultant for Aveo, Bristol Myers Squibb, Cullinan, Eisai, Exelixis, Genentech, Merck, Pfizer and Xilio; and received research funding from Alkermes, Bristol Myers Squibb, Exelixis, Genentech, Merck, Pfizer and X4 Pharma outside the submitted work. T.K.C. reports institutional and\/or personal support, paid and\/or unpaid, for research, advisory boards, consultancy and\/or honoraria, within the past 10 years, ongoing or not, from Alkermes, Aravive, Arcus Biosciences, AstraZeneca, AVEO Oncology, Bayer, Bicycle Therapeutics, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Circle Pharma, Deciphera Pharmaceuticals, Eisai, Eli Lilly, EMD Serono, Exelixis, GlaxoSmithKline, Gilead Sciences, HiberCell, Infinity Pharmaceuticals, Institut Servier, Ipsen, IQVIA, Janssen, Kanaph Therapeutics, Merck, Neomorph, Nikang Therapeutics, Novartis, Nuscan\/PrecedeBio, OncoHost, Pfizer, Roche, Sanofi\/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest Therapeutics, UpToDate and Xencor outside the submitted work. T.K.C. has also received support related to CME and non-CME educational activities from organizations including Clinical Care Options, Mashup Media, MJH Life Sciences, OncLive and PeerView; is named on filed institutional patents related to molecular alterations and immunotherapy response and toxicity, rare genitourinary cancers, and circulating tumour DNA and liquid biopsy technologies; holds equity in Abalytics, CureResponse, Faron Pharmaceuticals, Osel, Precede Bio, Primium and Tempest Therapeutics; has served on committees for the American Society of Clinical Oncology (Board of Directors from June 2024), European Society for Medical Oncology, KidneyCAN, and National Comprehensive Cancer Network, the US National Cancer Institute Genitourinary Cancers Steering Committee. The Dana\u2013Farber Cancer Institute might have received additional independent funding or royalties from pharmaceutical companies related to research in the subject area of this Review. M.M. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}